Farmamondo and AOP Orphan signs an exclusive registration, marketing and distribution agreement for AOP’s novel therapy Tetrabenazine indicated for Huntington disease. The agreement covers the territory of Russian federation and is valid for 5 years with relevant milestones. Farmamondo’s local affiliate will be responsible to achieve Marketing Authorization and commercially...

FarmaMondo approves Normokineztine in Russian Federation for Huntington disease patients. The product, license to FarmaMondo from AOP Orphan, has been approved as the sole indicated therapy currently available for Russian patients suffering from the indicated disease. FarmaMondo will launch the product in H1 2016 through...

FarmaMondo announces the approval of Ellanse, an innovative product in the esthetic segment, by the Taiwan local regulatory body – TFDA – as a medical device class II. The product was licensed to FarmaMondo on an exclusive basis for certain markets and has been approved as...

FarmaMondo SA announces it has established operations in Argentina to allow direct to hospital supply of unlicensed medicines, to cover spontaneous needs and in support of the company’s portfolio of Managed Access Programs. The Argentinian team will cover all local activities to support physicians and other stakeholders looking to fulfill...

FarmaMondo announces the establishment of its Brazilian subsidiary in Sao Paolo, Brazil. The subsidiary will facilitate the company’s vision and strategies in the Brazilian market and will leverage the company global capabilities to make certain, yet to be approved, therapies available to local patients...

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by ADIENNE to distribute Tepadina® via a Managed Access Program for targeted Healthcare Providers in selected global territories. Tepadina ®, an alkylating agent used with other medicines in the conditioning regimen before hematopoietic stem cell transplantation,...